Decisions by regulatory agencies: are they evidence-based?

Area of Science:

• Pharmacovigilance
• Drug Safety Regulation
• Cardiovascular Risk Assessment

Background:

• Discrepancies exist in regulatory statements from the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) concerning non-steroidal anti-inflammatory drugs (NSAIDs).
• Selective COX-2 inhibitors face stricter warnings in Europe compared to the US.
• Non-selective NSAIDs are perceived as safer in Europe than in the US, where they are equated with celecoxib's risk profile.

Discussion:

• Regulatory bodies have not fully acknowledged clinical trial data indicating significant variations in cardiovascular event risks among non-selective NSAIDs.
• Diclofenac demonstrates a notably higher risk of adverse cardiovascular events compared to other non-selective NSAIDs.
• The differing regulatory approaches raise concerns about the evidence-based nature of drug safety decisions.

Key Insights:

• European and US regulatory bodies present conflicting assessments of NSAID risks.
• Diclofenac poses a substantial cardiovascular risk, a fact inadequately addressed by current US regulations.
• There is a critical need for harmonized, evidence-based risk communication for NSAIDs globally.

Outlook:

• Future regulatory actions should prioritize a unified, risk-stratified approach to NSAID safety.
• Further research into comparative cardiovascular safety of NSAIDs is warranted.
• Enhanced international collaboration in pharmacovigilance can improve patient safety and regulatory consistency.